Cryoport
Runs cryogenic logistics, biostorage, and equipment for life-sciences materials.
Something off on this page? Send us feedback.
Profile
Provides temperature-controlled logistics, biostorage, cryopreservation support, software-enabled monitoring, and MVE cryogenic equipment for life-sciences customers. Revenue is split between Life Sciences Services and Life Sciences Products, with demand tied to cell-and-gene therapy trials, approved therapies, biorepository needs, and cryogenic-systems purchases.
Operates a temperature-controlled life-sciences platform across Cryoport Systems, CRYOGENE, and MVE Biological Solutions. Services include BioLogistics, BioStorage/BioServices, cryopreservation support, consulting, packaging, informatics, and monitoring across cryogenic, ultra-cold, refrigerated, and controlled-room-temperature ranges.
The product side is MVE, which sells cryogenic freezers, dewars, dry-vapor shippers, transport systems, and related accessories for life-sciences and animal-health customers. CRYOGENE adds U.S.-based biorepository storage for biological specimens and supplies.
Execution depends on compliance-heavy handling: Cryoportal software, Chain of Compliance, shipper requalification, traceability, and temperature-control expertise. The platform now excludes CRYOPDP after its DHL divestiture, and activity tracks cell-and-gene therapy development, approved therapies, biostorage demand, and cryogenic-equipment cycles.
Company facts
Categories
Key statistics
Year to date +68.3% · Average volume (30d) 562.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Needham | Reiterate | Buy | $15 | $19 |
| Aug 7, 2026 | Guggenheim | Reiterate | Buy | $12 | $16 |
| Aug 7, 2026 | Roth Capital | Reiterate | Buy | $21 | |
| Jul 24, 2026 | BTIG | Reiterate | Buy | $17 | $25 |
| Jun 8, 2026 | Jefferies | Target | $13 | $13.50 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.19 | −$0.20 | −3.5% | $48.2M | $49.0M | +1.6% | +2.79% |
| May 4, 2026Q1 FY26 | −$0.20 | −$0.23 | −15.0% | $44.9M | $47.8M | +6.5% | +19.39% |
| Mar 3, 2026Q4 FY25 | −$0.19 | −$0.21 | −10.5% | $42.9M | $45.5M | +6.1% | +2.94% |
| Nov 4, 2025Q3 FY25 | −$0.23 | −$0.18 | +21.7% | $42.9M | $44.2M | +3.0% | −7.48% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $41.0M | $45.5M | $44.2M | $45.5M | $47.8M | $49.0M | |
| Gross profit | $18.6M | $21.4M | $21.3M | $21.7M | $21.9M | $22.8M | |
| Operating income | −$9.5M | −$9.6M | −$9.9M | −$10.0M | −$9.6M | −$10.0M | |
| Net income | −$12.0M | $105.2M | −$6.9M | −$11.6M | −$9.4M | −$8.3M | |
| Diluted EPS | −$0.28 | $2.05 | −$0.18 | −$0.21 | −$0.23 | −$0.20 | |
| Gross margin | 45.4% | 47.0% | 48.2% | 47.8% | 45.8% | 46.6% | |
| Operating margin | -23.1% | -21.2% | -22.5% | -22.1% | -20.1% | -20.5% |
Fiscal years (4-quarter sums)FY21 $222.6M · FY22 $237.3M · FY23 $233.3M · FY24 $193.2M · FY25 $176.2M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $396.7M · Total debt $232.0M · Total assets $756.2M · Shareholders' equity $490.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 50.40M · Float 43.82M · 86.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.22M | 8.37% | 13F | Aug 7, 2026 |
| Integrated Core Strategies (US) LLC | 3.23M | 6.50% | 13G | Feb 5, 2026 |
| Cadian Capital Management, LP | 2.92M | 5.79% | 13F | Aug 14, 2026 |
| Morgan Stanley | 2.28M | 4.52% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 2.15M | 4.27% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 11, 2026 | Jerrell Shelton | director, officer: President, CEO | −28,800 | $14.91 |
| Jun 11, 2026 | Edward J. Zecchini | officer: Chief Digital and Tech Officer | −33,600 | $14.47 |
| Jun 10, 2026 | Edward J. Zecchini | officer: Chief Digital and Tech Officer | −1,400 | $15.23 |
| Jun 8, 2026 | Ramkumar Mandalam | director | −23,214 | $15.44 |
| Jun 4, 2026 | Robert Stefanovich | officer: Chief Financial Officer | −169,427 | $16.27 |
Peers
- Thermo Fisher Scientific
Biorepository services, biobanking tools, and cold-chain support
- Azenta
Sample management, biorepositories, and automated cryogenic storage
- Cencora
World Courier CGT logistics and cryogenic storage
- UPS
Healthcare cold chain and Marken clinical-trial logistics
- BioLife Solutions
CGT biopreservation media, cryogenic containers, and thawing tools
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cryoport | $16.09 | +0.03% | $811.0M | — | — | 4.3 | +7.7% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Azenta | $32.95 | −0.03% | $1.52B | — | 57.1 | 2.5 | +12.0% |
| Cencora | $320.00 | −0.60% | $62.65B | 23.9 | 16.6 | 0.2 | +5.1% |
| UPS | $105.33 | +0.01% | $89.47B | 19.6 | 13.6 | 1.0 | +7.4% |
| BioLife Solutions | $36.38 | −0.03% | $1.78B | 35.5 | 179.7 | 17.3 | +12.0% |
| Median | 28.7 | 23.7 | 2.5 | +10.5% |